7 results match your criteria: "University of Toronto - both in Toronto.[Affiliation]"
Wearable Digital Health Technology for Epilepsy.
N Engl J Med
February 2024
From the Division of Neurology, Hospital for Sick Children, and the Department of Paediatrics, University of Toronto - both in Toronto (E.D.); and the Epilepsy Center, Department of Neurology, New York University Grossman School of Medicine, New York (O.D., D.F.).
Sounding Out the Blood-Brain Barrier.
N Engl J Med
January 2024
From Sunnybrook Research Institute and the Department of Medical Biophysics and the Institute of Biomedical Engineering, University of Toronto - both in Toronto.
Two Phase 3 Trials of Gantenerumab in Early Alzheimer's Disease.
N Engl J Med
November 2023
From the Department of Neurology, Washington University School of Medicine, St. Louis (R.J.B.); Roche Products, Welwyn Garden City (J.S., C.L.), and the Department of Brain Sciences, Faculty of Medicine, Imperial College London (R.J.P.), and the Dementia Research Centre, Department of Neurodegenerative Disease, and the U.K. Dementia Research Institute, Queen Square Institute of Neurology, University College London (N.C.F.), London - all in the United Kingdom; the Alzheimer's Therapeutic Research Institute, Keck School of Medicine, University of Southern California, San Diego (M.C.D.), and Genentech, South San Francisco (T.B., R.S.D.) - both in California; F. Hoffmann-La Roche, Basel, Switzerland (P.D., R.A., J.W., T.B., G.K., A. Thanasopoulou, M. Baudler, P.F., R.S.D.); Butler Hospital and Warren Alpert Medical School, Brown University, Providence, RI (S.S.); the Department of Psychiatry and Neurochemistry, Sahlgrenska Academy, University of Gothenburg, and the Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital - both in Mölndal, Sweden (K.B.); the Division of Neurology, Department of Medicine, Sunnybrook Health Sciences Centre, and the L.C. Campbell Cognitive Neurology Research Unit, Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Research Program, Sunnybrook Research Institute, University of Toronto - both in Toronto (S.E.B.); the Ace Alzheimer Center Barcelona, Universitat Internacional de Catalunya, Barcelona, and the Networking Research Center on Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid - both in Spain (M. Boada); the Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany (T.G.); the Department of Neurology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan (A. Tamaoka); the Department of Neurology, Georgetown University School of Medicine, Washington, DC (R.S.T.); the Alzheimer's Research and Treatment Center, Wellington, FL (D.W.); the Medical and Cognitive Research Unit, Heidelberg Repatriation Hospital, Austin Health, Melbourne, VIC, Australia (M.W.); and the Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, Las Vegas (J.L.C.).
Article Synopsis
- Monoclonal antibodies like gantenerumab target amyloid-beta to potentially slow decline in Alzheimer’s symptoms, being a fully human anti-Aβ antibody.
- Two phase 3 trials (GRADUATE I and II) involved nearly 2,000 participants aged 50-90 with early signs of Alzheimer’s, comparing gantenerumab with a placebo over 116 weeks.
- Although the trials showed some differences in amyloid levels and cognitive scores between tretament groups, the results were not statistically significant, indicating gantenerumab might not significantly alter cognitive decline compared to placebo.
Case 22-2023: A 59-Year-Old Woman with Hypotension and Electrocardiographic Changes.
N Engl J Med
July 2023
From the Department of Anesthesia and Pain Management, Toronto General Hospital, and the Department of Anesthesia and Pain Medicine, University of Toronto - both in Toronto (W.A.K.); the Division of Anesthesiology, Intensive Care, and Emergency Medicine, University Medical Center Utrecht, the Netherlands (W.A.K.); and the Departments of Anesthesia, Critical Care, and Pain Medicine (M.D.S.) and Medicine (P.E.H.), Massachusetts General Hospital, and the Departments of Anesthesia, Critical Care, and Pain Medicine (M.D.S.) and Medicine (P.E.H.), Harvard Medical School - both in Boston.
The U.S. Insulin Crisis - Rationing a Lifesaving Medication Discovered in the 1920s.
N Engl J Med
November 2019
From Mount Sinai Hospital and the Division of General Internal Medicine, Department of Medicine, University of Toronto - both in Toronto (M.F.); and the Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston (A.K.).
Neonatal Intensive Care - The Only Constant Is Change.
N Engl J Med
February 2017
From the Department of Pediatrics and Institute of Health Policy, Management, and Evaluation, Mount Sinai Hospital, and the University of Toronto - both in Toronto.
Ventilator-induced lung injury.
N Engl J Med
November 2013
From the Keenan Research Center, Li Ka Shing Knowledge Institute, St. Michael's Hospital, and the Department of Medicine and Interdepartmental Division of Critical Care Medicine, University of Toronto - both in Toronto (A.S.S.); and Dipartimento di Anestesia e Medicina degli Stati Critici, Ospedale S. Giovanni Battista Molinette, Università di Torino, Turin, Italy (V.M.R.).